Leptin induces functional activation of cyclooxygenase-2 through JAK2/ STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells

Cancer Science

Volumn 100, Issue 3, 2009, Pages 389-395

  Gao, Jingchun ^a,b   Tian, Jianxin ^a   Lv, Yunyi ^a   Shi, Fangxin ^a   Kong, Fandou ^a   Shi, Hong ^a   Zhao, Liyan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROSTAGLANDIN E2; PROTEIN KINASE B; STAT3 PROTEIN; THYMIDINE; JAK2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; ENZYME INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; ENDOMETRIUM TUMOR; FEMALE; IMMUNOASSAY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOASSAY; JANUS KINASE 2; LEPTIN; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LEPTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 62849109985     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01053.x     Document Type: Article

References (54)

1. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 14: 1132-42.
2. Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: A review. Obstet Gynecol Surv 2005; 60: 683-92.
3. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005; 90: 207-10.
4. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-7.
5. Rouet-Benzineb P, Aparicio T, Guilmeau S et al. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem 2004; 279: 16495-502.
6. Yin N, Wang D, Zhang H et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 2004; 64: 5870-5.
7. White DW, Tartaglia LA. Leptin and OB-R: Body weight regulation by a cytokine receptor. Cytokine Growth Factor Rev 1996; 7: 303-9.
8. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-71.
9. Fei H, Okano HJ, Li C et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 1997; 94: 7001-5.
10. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-95.
11. Yamashita T, Murakami T, Otani S, Kuwajima M, Shima K. Leptin receptor signal transduction. OBRa and OBRb of fa type. Biochem Biophys Res Commun 1998; 246: 752-9.
12. Yuan SS, Tsai KB, Chung YF et al. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. Gynecol Oncol 2004; 92: 769-75.
13. Yuan SS, Chung YF, Chen HW et al. Aberrant expression and possible involvement of the leptin receptor in bladder cancer. Urology 2004; 63: 408-13.
14. Bado A, Levasseur S, Attoub S et al. The stomach is a source of leptin. Nature 1998; 394: 790-3.
15. Caprio M, Fabbrini E, Isidori AM, Aversa A, Fabbri A. Leptin in reproduction. Trends Endocrinol Metab 2001; 12: 65-72.
16. Shida D, Kitayama J, Mori K, Watanabe T, Nagawa H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 2005; 65: 9159-63.
17. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2002; 94: 1704-11.
18. Pai R, Lin C, Tran T, Tarnawski A. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 2005; 331: 984-92.
19. Ogunwobi OO, Beales IL. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007; 22: 401-9.
20. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006; 147: 4505-16.
21. Liu CH, Chang SH, Narko K et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.
22. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94: 3336-40.
23. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
24. Gao J, Niwa K, Takemura M et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol 2005; 26: 737-44.
25. Gao J, Niwa K, Sun W et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 2004; 95: 901-7.
26. Li M, Wu X, Xu XC. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 2001; 7: 1010-16.
27. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003; 9: 1885-97.
28. Milella M, Metro G, Gelibter A, Pino SM, Cognetti F, Fabi A. COX-2 targeting in cancer: A new beginning? Ann Oncol 2008; 19: 1209-10.
29. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007; 7: 599-608.
30. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 2006; 45: 447-54.
31. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: Progress and perspective. Cancer Lett 2004; 215: 1-20.
32. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999; 274: 5038-46.
33. Matsuura H, Sakaue M, Subbaramaiah K et al. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem 1999; 274: 29138-48.
34. Rodriguez-Barbero A, Dorado F, Velasco S, Pandiella A, Banas B, Lopez-Novoa JM. TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. Kidney Int 2006; 70: 901-9.
35. Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 2006; 13: 629-40.
36. Nishida M, Kasahara K, Kaneko M, Iwasaki H. Establishment of a new endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynaecol Jpn 1985; 37: 1103-11.
37. Clarke CL, Feil PD, Satyaswaroop PG. Progesterone receptor regulation by 17 beta-estradiol in human endometrial carcinoma grown in nude mice. Endocrinology 1987; 121: 1642-8.
38. Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn 1972; 19: 47-58.
39. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972; 114: 1012-19.
40. Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 1983; 19: 147-58.
41. Dawe CJ, Banfield WG, Morgan WD, Slatick MS, Curth HO. Growth in continuous culture, and in hamsters, of cells from a neoplasm associated with acanthosis nigricans. J Natl Cancer Inst 1964; 33: 441-56.
42. Petridou E, Belechri M, Dessypris N et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 2002; 46: 147-51.
43. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-9.
44. Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Weight change and risk of endometrial cancer. Int J Epidemiol 2006; 35: 151-8.
45. Xu WH, Xiang YB, Zheng W et al. Weight history and risk of endometrial cancer among Chinese women. Int J Epidemiol 2006; 35: 159-66.
46. Tessitore L, Vizio B, Pesola D et al. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 2004; 24: 1529-35.
47. Attoub S, Noe V, Pirola L et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. Faseb J 2000; 14: 2329-38.
48. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H. Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle. J Clin Endocrinol Metab 2000; 85: 1946-50.
49. Bogusiewicz M, Semczuk A, Gogacz M, Skomra D, Jakowicki JA, Rechberger T. Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas. Cancer Lett 2006; 238: 61-8.
50. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res 2006; 55: 233-44.
51. Zerani M, Boiti C, Dall'Aglio C et al. Leptin receptor expression and in vitro leptin actions on prostaglandin release and nitric oxide synthase activity in the rabbit oviduct. J Endocrinol 2005; 185: 319-25.
52. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002; 137: 799-804.
53. O'Rourke L, Shepherd PR. Biphasic regulation of extracellular-signal-regulated protein kinase by leptin in macrophages: role in regulating STAT3 Ser727 phosphorylation and DNA binding. Biochem J 2002; 364: 875-9.
54. Coffey RJ, Hawkey CJ, Damstrup L et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997; 94: 657-62.